0000000000668150
AUTHOR
C. Carrera
Examining the generalizability of research findings from archival data
This research project benefitted from Ministry of Education (Singapore) Tier 1 Grant R-313-000-131-115 (to A. Delios), National Science Foundation of China Grants 72002158 (to H.T.) and 71810107002 (to H.T.), grants from the Knut and Alice Wallenberg Foundation (to A. Dreber) and the Marianne and Marcus Wallenberg Foundation (through a Wallenberg Scholar grant; to A. Dreber), Austrian Science Fund (FWF) Grant SFB F63 (to A. Dreber), grants from the Jan Wallander and Tom Hedelius Foundation (Svenska Handelsbankens Forskningsstiftelser; to A. Dreber), and an Research & Development (R&D) research grant from Institut Européen d'Administration des Affaires (INSEAD) (to E.L.U.). Dmitrii Dubrov, o…
Pruritus characteristics in a large Italian cohort of psoriatic patients
Background: Psoriasis (Ps) is a chronic systemic autoimmune disease associated with pruritus in 64–98% of patients. However, few modestly sized studies assess factors associated with psoriatic pruritus. Objective: To investigate factors associated with Ps pruritus intensity. Methods: Psoriasis patients 18 years or older seen in one of 155 centres in Italy between September 2005 and 2009 were identified from the Italian PsoCare registry. Patients without cutaneous psoriasis and those with missed information on pruritus were excluded. Results: We identified 10 802 patients, with a mean age 48.8 ± 14.3 years. Mild itch was present in 33.2% of patients, moderate in 34.4%, severe in 18.7% and ve…
Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry
Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis …
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study
AbstractBackgroundPsoriasis is a chronic immune-mediated inflammatory skin disease which can also involve joints. It is often associated with burdensome comorbidities which negatively impact prognosis and quality of life (QoL). Biologic agents have been shown to be effective in controlling disease progression, but their use is associated with higher costs compared with traditional systemic treatments. The economic analysis of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: an obserVAtional longitudinal study of real-life clinical practice) study aims to assess the costs and cost-effectiveness of biologics in a real-world context in Italy.MethodsThe annualised…